Ashford Capital Management Inc. Has $20.25 Million Stock Position in Cellebrite DI Ltd. $CLBT

Ashford Capital Management Inc. lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,265,670 shares of the company’s stock after purchasing an additional 27,830 shares during the quarter. Cellebrite DI makes up about 2.4% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 14th largest position. Ashford Capital Management Inc. owned 0.53% of Cellebrite DI worth $20,251,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Voss Capital LP boosted its holdings in Cellebrite DI by 34.0% during the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after purchasing an additional 1,306,398 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Cellebrite DI by 17.1% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after buying an additional 570,000 shares during the period. Invesco Ltd. boosted its stake in Cellebrite DI by 6.4% in the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after buying an additional 209,473 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Cellebrite DI in the first quarter valued at $60,939,000. Finally, Pertento Partners LLP raised its stake in Cellebrite DI by 11.8% during the second quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock worth $47,130,000 after acquiring an additional 309,988 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

CLBT opened at $18.82 on Friday. The stock has a fifty day moving average of $17.76 and a 200-day moving average of $16.58. The company has a market capitalization of $4.51 billion, a P/E ratio of 60.71, a P/E/G ratio of 3.21 and a beta of 1.29. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The business had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm’s quarterly revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 earnings per share. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CLBT has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 8th. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Lake Street Capital upped their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Bank of America boosted their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.